Merck KGaA (FRA:MRK)‘s stock had its “buy” rating reissued by stock analysts at DZ Bank in a report issued on Monday.
A number of other analysts have also recently weighed in on the company. UBS Group reiterated a “buy” rating on shares of Merck KGaA in a research report on Monday, January 15th. JPMorgan Chase & Co. set a €100.00 ($123.46) price target on Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, December 12th. Kepler Capital Markets set a €115.00 ($141.98) price target on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Nord/LB reiterated a “neutral” rating on shares of Merck KGaA in a research report on Wednesday, December 27th. Finally, Sanford C. Bernstein set a €115.00 ($141.98) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Wednesday, January 17th. Twelve research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of €102.00 ($125.93).
Shares of Merck KGaA (FRA MRK) traded up €1.04 ($1.28) during trading on Monday, hitting €79.30 ($97.90). The stock had a trading volume of 1,605 shares. The firm has a market cap of $10,280.00 and a PE ratio of 13.26. Merck KGaA has a fifty-two week low of €76.60 ($94.57) and a fifty-two week high of €115.00 ($141.98).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.